# Second Quarter Fiscal 2027 Results

November 5, 2026

© 2026 Haemonetics Corporation

HAEMONETICS®

# Q2 Fiscal 2027 Conference Call Detail

Conference call will take place at **8:00 a.m. ET** on **November 5, 2026,** and can be accessed via live webcast: Link or teleconference: Link.

The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 a.m. ET) are available online at www.haemonetics.com.

## CONFERENCE CALL SPEAKERS

**Chris Simon**
President & CEO

**James D'Arecca**
EVP, Chief Financial Officer

**Olga Guyette**
VP, Investor Relations & Treasury



HAEMONETICS®

# Important Information

**Safe Harbor for Forward-Looking Statements**
Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the Company's strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company's market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company's share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above.

Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, availability and demand for the Company's products; the Company's ability to successfully develop and market new products and technologies; the impact of competitive products and pricing; product quality; disruptions caused by cybersecurity events; any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures; pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation; manufacturing, distribution and supply chain disruptions and cost increases; the Company's ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative; the effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures; regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions; indebtedness incurred by the Company, including the conditional conversion feature of its convertible notes; the Company's ability to protect its intellectual property; litigation; and the impact of share repurchases on the Company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase program's effectiveness. These and other factors are identified and described in more detail in the Company's periodic reports and other filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company does not undertake to update these forward-looking statements.

**Non-GAAP Financial Measures**
This presentation contains financial measures that are considered "non-GAAP" financial measures under applicable SEC rules and regulations. Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are also based on certain non-GAAP financial measures. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company's reported financial results prepared in accordance with U.S. GAAP. In this presentation, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company's core operations and provide a baseline for analyzing trends in the Company's underlying businesses. We strongly encourage investors to review the Company's financial statements and publicly-filed reports in their entirety and not rely on any single financial measure.

When used in this presentation, organic revenue growth excludes the impact of currency fluctuation and the exit of certain liquid solution products. Adjusted gross profit, adjusted operating expenses, adjusted operating income, adjusted interest and other income/expense, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition and integration related costs, certain tax settlements, unusual or infrequent and material litigation-related charges, equity method losses, impairment of intangible assets, and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies.

A reconciliation of non-GAAP historical financial measures to their most comparable GAAP measure are included at the end of the financial sections of this presentation as well as on the Company's website at www.haemonetics.com. The Company does not attempt to provide reconciliations of forward-looking adjusted operating margin guidance, adjusted earnings per diluted share guidance or free cash flow conversion guidance to the comparable GAAP measures because the combined impact and timing of recognition of certain potential charges or gains, such as restructuring costs, impairment charges and capital expenditures, is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of the Company's financial performance.

**Use of Document**
This presentation contains certain highlights with respect to our second quarter of fiscal 2027 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our earnings release for the second quarter ended September 26, 2026 located in the investor relations section of our website at www.haemonetics.com and our Quarterly Report on Form 10-Q for the quarter ended September 26, 2026 filed with the SEC.

# Q2 Fiscal 2027 Highlights

## Broad-based profitable growth

**$358M**

REVENUE

| 9.3% | 10.0% |
|---|---|
| reported | organic |

EARNINGS PER SHARE

| $1.00 | $1.35 |
|---|---|
| GAAP | Adjusted |
| +23% Y/Y | +6% Y/Y |

## Major milestones advance our growth strategy

### Expanded CSL relationship

- CSL currently anticipates completing the rollout of NexSys® with Persona® PLUS across all its current U.S. plasma collection centers by year-end 2027.

### Achieved key regulatory milestones in Vascular Closure

- Received U.S. FDA approval for PerQSeal® Elite.
- CE Mark certification and Japanese regulatory approval for the expanded indication of VASCADE MVP® XL.

### Launched PacePro™ guidewire in the U.S.

## Strong cash generation expands financial flexibility

**$128M** +15% Y/Y

OPERATING CASH FLOW

**$104M** +17% Y/Y

FREE CASH FLOW

FCF conversion[1]

| 166% | 111% |
|---|---|
| Q2 | TTM[2] |

1) FCF conversion = free cash flow ÷ adjusted net income × 100. FCF = operating cash flow less capital expenditures and equipment additions, plus PP&E sale proceeds. 2) TTM uses four-quarter totals through September 26, 2026. Conversion measures FCF per dollar of adjusted net income; 111% means $1.11 per $1.



HAEMONETICS®

# PacePro™ guidewire broadens our TAVR reach while preserving SavvyWire's differentiated position

A familiar, pacing-enabled workhorse wire expands physician choice through the same commercial infrastructure.

## PACEPRO™

**Engineered to perform. Cleared to pace.**



**150K+** **U.S. TAVR procedures annually**[1]

Familiar workflow • On-label LV pacing • 280 cm

## STRATEGIC RATIONALE

### 01 Expands participation in TAVR

Addresses physicians who prefer a traditional pacing workflow, broadening the portion of the market Haemonetics can serve.

### 02 Complements SavvyWire®

SavvyWire remains the flagship sensor-guided platform; PacePro adds a familiar workhorse option for a distinct physician preference.

### 03 Capital-efficient commercialization

Uses the existing Interventional Technologies sales organization, with no meaningful incremental salesforce or commercial infrastructure investment.

| PRODUCT AT A GLANCE | FDA 510(k) cleared | Temporary intracardiac pacing | Single-wire workflow simplification |
|---|---|---|---|



1) S2N Health data on file.


HAEMONETICS®

# PerQseal® Elite FDA approval rounds out our vascular closure portfolio

Coverage from 5F to 22F in sheath inner diameter, with large-bore arterial closure up to 26F arteriotomy size

## COMPLETE VASCULAR CLOSURE PORTFOLIO

| VASCADE® | VASCADE MVP® | VASCADE MVP® XL | PerQseal® Elite |
|---|---|---|---|
|  |  |  |  |
| **5–7F** | **6–12F** | **8–14F** | **14–22F** |
| Arterial and venous | Venous | Venous | Arterial[1] |
| | Up to 15F OD | Up to 17F OD | Up to 26F OD |




Procedural sheath sizes shown in French (F), inner diameter

## PERQSEAL ELITE OPPORTUNITY

**~$300M**

**Estimated global large-bore TAM[2]**
**Growing high single digits**

### Differentiated closure

**Fully bioabsorbable:** Sutureless patch

**Rapid Hemostasis:** Mean time to hemostasis <1 minute[3]

**Safety Profile**: 0% major VARC-3 complications[4]

### A path to category leadership

Expands structural heart and endovascular reach, leveraging our existing commercial scale

1) U.S. PerQseal® Elite scope: arterial indication. 2) January 2026 estimate includes global arterial and venous procedures >14F, not only the U.S. indication. TAM = procedures × expected ASP. 3) Results from the prospective, single-arm, multi-center ELITE study. 4) Results from the prospective, single-arm, multi-center ELITE Arterial study; VARC-3 Major device-related vascular access site complications (adjudicated) through 30 days..




HAEMONETICS®

# Q2 Fiscal 2027 Revenue by Business Unit

**REVENUE**

(in millions)




| (in millions) | Q2 2027 | Q2 2026 | REPORTED GROWTH | ORGANIC GROWTH[1] |
|---|---|---|---|---|
| Plasma | $162.6 | $139.6 | 16.5% | 17.7% |
| Other[2] | $42.2 | $42.2 | - | 0.2% |
| **Apheresis** | **$204.8** | **$181.8** | **12.6%** | **13.6%** |
| Interventional Technologies[3] | $60.5 | $59.1 | 2.4% | 3.2% |
| Blood Management Technologies[4] | $92.4 | $86.4 | 7.0% | 7.0% |
| **MedSurg** | **$153.0** | **$145.5** | **5.1%** | **5.5%** |
| **Total Net Revenues** | **$357.8** | **$327.3** | **9.3%** | **10.0%** |

1) Includes the impact of the exit of certain liquid solution products and nominal historical pre-acquisition revenue of Vivasure. 2) Other includes blood collection and processing devices and disposables. 3) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the MedSurg business unit.



HAEMONETICS®



# Q2 Fiscal 2027 Financial Review

## GAAP RESULTS

| | Q2 2027 | Q2 2026 | Y/Y |
|---|---|---|---|
| **Gross Margin %** | 61.7% | 59.5% | +220bps |
| **Operating Margin %** | 21.0% | 17.9% | +310bps |
| **Net Income Margin %** | 12.9% | 11.8% | +110bps |
| **Income Tax Rate** | 26.3% | 24.6% | +170bps |
| **Earnings Per Share** | $1.00 | $0.81 | 23% |

## NON-GAAP RESULTS

| | Q2 2027 | Q2 2026 | Y/Y |
|---|---|---|---|
| **Adjusted Gross Margin %** | 61.9% | 60.5% | +140bps |
| **Adjusted Operating Margin %** | 26.3% | 26.7% | -40bps |
| **Adjusted Net Income Margin %** | 17.5% | 18.4% | -90bps |
| **Adjusted Income Tax Rate** | 24.7% | 24.7% | - bps |
| **Adjusted Earnings Per Share** | $1.35 | $1.27 | 6% |



# Q2 Fiscal 2027 Segment Performance

## APHERESIS

| | Q2 2027 | Q2 2026 | Y/Y |
|---|---|---|---|
| **Revenue** | $204.8M | $181.8M | 12.6% reported / 13.6% organic |
| **Segment Operating Margin %[1]** | 30.5% | 31.6% | -110bps |

## MEDSURG

| | Q2 2027 | Q2 2026 | Y/Y |
|---|---|---|---|
| **Revenue** | $153.0M | $145.5M | 5.1% reported / 5.5% organic |
| **Segment Operating Margin %[1]** | 20.7% | 20.5% | +20bps |


1) Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include amortization of acquired intangible assets, amortization of fair value inventory step-up, acquisition and integration related costs, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of the Company's enterprise resource planning system, unusual or infrequent and material litigation-related charges and gains, impairment of intangible assets, and remeasurement of the contingent consideration. Total corporate and unallocated expenses were $18.9M in Q2 FY'27 and $28.8M in Q2 FY'26. Please refer to the reconciliation table in Appendix D of this presentation for more information.



HAEMONETICS®

# Balance Sheet and Cash Flow Metrics

## CASH FROM OPERATIONS




| (in millions) | 9/26/26 | 3/28/26 |
|---|---|---|
| **Cash & cash equivalents** | $261 | $245 |
| **Working capital** | $555 | $552 |
| **Total debt** | $1,124 | $1,225 |
| **Net debt[1]** | $863 | $979 |
| **Available credit[2]** | $549 | $449 |
| **Gross leverage ratio[3]** | 2.63 | 2.97 |
| **Net leverage ratio[3]** | 2.46 | 2.73 |

1) Net debt is calculated as total debt minus cash & cash equivalents. 2) Available borrowing capacity under the existing revolving credit facility minus any eligible letters of credit. 3) Gross and net leverage ratios per the terms set forth in the Company's existing credit agreement. 4) Includes capital expenditures, non-cash inventory transfers of Haemonetics equipment and proceeds from the sale of property, plant and equipment.



HAEMONETICS®

# Full-Year Fiscal 2027 Guidance

| | GUIDANCE AS OF AUGUST 6, 2026 | GUIDANCE AS OF NOVEMBER 5, 2026 |
|---|---|---|
| **Reported Revenue** | **5 – 8%** | **8 – 11%** |
| 53rd Week Impact | (~2%) | (~2%) |
| Strategic exits[1] | ~1% | ~1% |
| Currency Impact | 0 – 1% | 0 – 1% |
| **Organic Revenue[2]** | **4 – 7%** | **6 – 9%** |
| Apheresis | LSD to MSD Growth | HSD Growth |
| MedSurg | MSD Growth | MSD Growth |
| **Adjusted Operating Margin** | **50 – 100 bps expansion YoY** | **0 – 50 bps expansion YoY** |
| **Adjusted EPS** | **Comparable to reported revenue growth** | **Comparable to reported revenue growth** |
| **Free cash flow conversion[3]** | **~80%** | **>80%** |



1) Includes the impact of the exit of certain liquid solution products. 2) Organic growth guidance also includes nominal historical pre-acquisition revenue of Vivasure to provide a comparable view of period-over-period performance. 3) Free cash flow conversion is calculated as free cash flow divided by adjusted net income.

# Appendices


© 2026 Haemonetics Corporation

# Appendix A: Reconciliation of GAAP to Organic Revenue Growth Rates

| ($ millions)<br>**Revenues by business unit** | Q2 2027 | Q2 2026 | Reported growth | Currency impact | Acquisitions & Divestitures[1] | Organic growth[2] |
|---|---|---|---|---|---|---|
| Plasma | $162.6 | $139.6 | 16.5% | (0.6%) | (0.6%) | 17.7% |
| Other[3] | $42.2 | $42.2 | – | (0.2%) | – | 0.2% |
| **Apheresis** | $204.8 | $181.8 | 12.6% | (0.6%) | (0.4%) | 13.6% |
| Interventional Technologies[4] | $60.5 | $59.1 | 2.4% | (0.8%) | – | 3.2% |
| Blood Management Technologies[5] | $92.4 | $86.4 | 7.0% | – | – | 7.0% |
| **MedSurg** | $153.0 | $145.5 | 5.1% | (0.4%) | – | 5.5% |
| **Total Net Revenues** | $357.8 | $327.3 | 9.3% | (0.4%) | (0.3%) | 10.0% |

1) Includes the impact of the exit of certain liquid solution products. 2) Includes nominal historical pre-acquisition revenue of Vivasure. 3) Other includes blood collection and processing devices and disposables. 4) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the MedSurg business unit. 5) Blood Management Technologies includes Hemostasis Management, Cell Salvage, and Transfusion Management product lines of the MedSurg business unit.



HAEMONETICS®

# Appendix B: Reconciliation of GAAP to Non-GAAP
# Q2 Fiscal 2027 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income | Interest and other (expense) income | Provision for income taxes | Net income (Loss) | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| **Reported** | $220.9 | $145.8 | $75.1 | ($12.3) | $16.6 | $46.3 | $1.00 |
| Amortization of acquired intangible assets | – | ($10.4) | $10.4 | – | $2.2 | $8.2 | $0.18 |
| Integration and transaction costs | $0.9 | ($1.6) | $2.6 | – | $0.1 | $2.5 | $0.05 |
| Restructuring costs | ($0.2) | – | ($0.2) | – | – | ($0.2) | – |
| Restructuring related costs | – | – | – | – | – | – | – |
| Digital transformation costs | – | ($5.4) | $5.4 | – | $1.3 | $4.1 | $0.09 |
| Litigation-related charges | – | – | – | – | – | – | – |
| Remeasurement of contingent consideration | – | ($0.7) | $0.7 | – | $0.2 | $0.6 | $0.01 |
| Equity method losses | – | – | – | $1.4 | $0.3 | $1.0 | $0.02 |
| Discrete tax items | – | – | – | – | – | – | – |
| **Adjusted** | $221.6 | $127.6 | $94.1 | ($10.9) | $20.6 | $62.6 | $1.35 |
| **Adjusted, as a percentage of net revenues** | 61.9% | 35.7% | 26.3% | | | 17.5% | |



HAEMONETICS®

# Appendix B: Reconciliation of GAAP to Non-GAAP
# Q2 Fiscal 2026 Financial Results

| ($ millions) | Gross profit | Operating expenses | Operating income | Interest and other expense | Provision for income taxes | Net income | Earnings per diluted share |
|---|---|---|---|---|---|---|---|
| **Reported** | $194.7 | $136.3 | $58.5 | ($7.2) | $12.6 | $38.7 | $0.81 |
| Amortization of acquired intangible assets | – | ($11.2) | $11.2 | – | $2.8 | $8.4 | $0.19 |
| Amortization of fair value inventory step up | $2.1 | – | $2.1 | – | $0.5 | $1.6 | $0.03 |
| Integration and transaction costs | $1.3 | ($0.2) | $1.5 | – | $0.4 | $1.1 | $0.02 |
| Restructuring costs | ($0.1) | ($0.3) | $0.2 | – | – | $0.1 | – |
| Restructuring related costs | – | – | $0.1 | – | – | – | – |
| Digital transformation costs | – | ($5.1) | $5.1 | – | $1.2 | $3.8 | $0.08 |
| Litigation-related charges | – | ($0.2) | $0.2 | – | – | $0.2 | – |
| Impairment of intangible assets | – | ($8.6) | $8.6 | – | $2.1 | $6.4 | $0.14 |
| Remeasurement of contingent consideration | – | $0.1 | ($0.1) | – | ($0.1) | – | – |
| **Adjusted** | $198.0 | $110.8 | $87.3 | ($7.2) | $19.8 | $60.3 | $1.27 |
| **Adjusted, as a percentage of net revenues** | 60.5% | 33.8% | 26.7% | | | 18.4% | |



HAEMONETICS®

# Appendix C: Reconciliation of Cash Flows

| ($ millions) | Q2 2027 | Q2 2026 | FY 2027 | FY 2026 |
|---|---|---|---|---|
| **Free Cash Flow Reconciliation** | | | | |
| Cash provided by operating activities | $128.1 | $111.3 | $180.4 | $128.7 |
| Capital expenditures | ($14.8) | ($5.0) | ($22.7) | ($8.8) |
| Additions to Haemonetics equipment | ($10.1) | ($17.7) | ($15.7) | ($29.1) |
| Proceeds from sale of property, plant and equipment | $0.6 | $0.1 | $0.8 | $0.4 |
| **Free cash flow** | $103.8 | $88.7 | $142.9 | $91.2 |

# Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2)

| ($ millions) | Q2 2027 | Q2 2026 |
|---|---|---|
| **Net revenues:** | | |
| Apheresis | $204.8 | $181.8 |
| MedSurg | $153.0 | $145.5 |
| **Total net revenues** | **$357.8** | **$327.3** |
| **Significant segment expenses and operating performance:** | | |
| **Apheresis** | | |
| Cost of goods sold | $88.5 | $80.0 |
| Selling, general and administrative | $47.3 | $38.3 |
| Research and development | $6.6 | $6.2 |
| Apheresis operating income | $62.4 | $57.4 |
| **MedSurg** | | |
| Cost of goods sold | $47.7 | $49.3 |
| Selling, general and administrative | $63.8 | $58.0 |
| Research and development | $9.9 | $8.4 |
| MedSurg operating income | $31.7 | $29.9 |



HAEMONETICS®

# Appendix D: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2)

| ($ millions) | Q2 2027 | Q2 2026 |
|---|---|---|
| **Corporate and unallocated expenses** | | |
| Amortization of acquired assets | ($10.4) | ($13.2) |
| Integration and transaction costs | ($2.6) | ($1.5) |
| Restructuring and restructuring related costs | $0.2 | ($0.3) |
| Digital transformation costs | ($5.4) | ($5.1) |
| Other[1] | ($0.8) | ($8.7) |
| Operating income | $75.1 | $58.5 |
| Interest and other expense, net | ($12.3) | ($7.2) |
| **Income before provision for income taxes** | **$62.9** | **$51.3** |

1) Comprised of intangible asset impairments, litigation-related charges and remeasurement of contingent consideration for the three months ended September 26, 2026 and September 27, 2025.



HAEMONETICS®

# Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results[1]

| ($ millions) | TTM Q2 FY27 Net income (loss) | TTM Q2 FY26 Net income (loss) |
|---|---|---|
| **Reported** | $103.9 | $168.2 |
| Amortization of acquired intangible assets | $32.5 | $34.5 |
| Amortization of fair value inventory step up | $1.0 | $7.9 |
| Acquisition, Integration, transaction and divestiture costs | $14.1 | $8.2 |
| Restructuring costs | $2.8 | $4.3 |
| Restructuring related costs | – | $2.5 |
| Digital transformation costs | $17.2 | $14.8 |
| Write downs of certain in-process intangible assets and PCS2 related charges | $0.7 | $3.0 |
| MDR and IVDR costs | – | $2.1 |
| Litigation-related charges | ($0.1) | $2.0 |
| Impairment of intangible assets | $58.9 | $6.4 |
| Remeasurement of contingent consideration | ($0.9) | ($20.9) |
| Provision for pre-acquisition inventory | $5.5 | – |
| Equity method losses | $1.8 | – |
| Discrete tax items | ($1.2) | $2.4 |
| **Adjusted** | $236.0 | $235.4 |
| **Adjusted, as a percentage of net revenues** | 17.1% | 17.7% |

| ($ millions) | TTM Q2 FY27 | TTM Q2 FY26 |
|---|---|---|
| **Free Cash Flow Reconciliation** | | |
| Cash provided by operating activities | $344.9 | $289.0 |
| Capital expenditures | ($46.7) | ($33.0) |
| Additions to Haemonetics' equipment | ($38.4) | ($43.5) |
| Proceeds from sale of property, plant and equipment | $1.8 | $3.1 |
| **Free cash flow** | $261.6 | $215.7 |



1) Reflects non-GAAP adjustments for each of the four subsequent quarters ending September 26, 2026 and September 27, 2025, respectively.

HAEMONETICS®